Replies to post #205844 on Biotech Values

[dewophile]

I've posted multiple times that immunogenicity is something I'm curious about

I'm curious what makes you curious. Is it more of a concern with fusion proteins like this, or perhaps the high rate of infusion reaction?

I'm also a little surprised that the abstract notes some duration of stable disease but no explicit mention of any objective responses.

I just assumed there were no objective responses by virtue of omission, but you're right the abstract was not explicit on this point. It's not like they stated best response so far was SD and truth is we don't know about the other 4 pts still on drug

[DFRAI]

TRIL

Do you think that company would move forward into expansion of heme trials and also start solid tumours if they had issues you talked about? TIA